UBS Downplays G7 CGM Sensor Concerns, Affirms DexCom’s Inc. (DXCM) ‘Buy’ Rating

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ ...
MedTech Dive

Biolinq gets FDA de novo nod for intradermal glucose sensor

The device, called Biolinq Shine, is indicated for people with Type 2 diabetes who don’t depend on insulin. Biolinq says its ...

Forecasting The Future: 10 Analyst Projections For DexCom

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $99.3, a high estimate of $106.00, and a low estimate of $89.00. Marking an ...

You can now upgrade a retro Casio watch with Bluetooth, step tracking, and games

For the first time since it launched 36 years ago, the iconic Casio F-91W digital watch is getting some smart upgrades — but ...
Becker's Hospital Review

Inside Temple Health’s predictive insulin rollout: What worked and what’s next

After launching a multi-campus phased rollout of the predictive insulin dosing software, Philadelphia-based Temple Health’s University Hospital has reduced hypoglycemia rates two- to threefold.   The ...